Accumulation of tau and amyloid- are two pathologic hallmarks of Alzheimer's disease (AD). Here, we conducted an epigenome-wide association study using the H3K9 acetylation (H3K9Ac) mark in 669 aged human prefrontal cortices: in contrast to amyloid-, tau protein burden had a broad effect on the epigenome, affecting 5,590 out of 26,384 H3K9Ac domains. Tau-related alterations aggregated in large genomic segments reflecting spatial chromatin organization, and the magnitude of these effects correlated with the segment's nuclear lamina association. We confirmed the functional relevance of these chromatin changes by demonstrating (1) consistent transcriptional changes in three independent datasets and (2) similar findings in two AD mouse models. Finally, we found that tau overexpression in iPSC-derived neurons disrupted chromatin organization and that these effects could be blocked by a small molecule predicted to reverse the tau effect. Thus, we report large-scale tau-driven chromatin rearrangements in the aging human brain that may be reversible with HSP90 inhibitors.
Introduction
Alzheimer's disease (AD) is a chronic neurodegenerative disease characterized pathologically by the accumulation of amyloid- plaques and tau tangles which leads to neuronal cell death, cognitive impairment, and, ultimately, a diagnosis of dementia. Although loci harboring genetic risk factors have been identified in genome-wide studies 1 , a large portion of late onset AD dementia risk remains unexplained, indicating the need for complementary approaches such as exploring the aging brain's epigenome. Epigenomic alterations can be caused by genetic and non-genetic risk factors such as life experiences and environmental exposures but can also occur as a consequence of AD pathologies 2 .
Hence, studying the AD epigenome may also be helpful for understanding molecular events resulting from the toxicity of AD pathologies. Evidence for epigenomic perturbations in AD was found in smaller human studies 3 , but, so far, AD-related epigenome-wide association studies of the human cortex have been limited to DNA methylation 4, 5 . These studies were important in demonstrating reproducible DNA methylation changes in AD subjects, but did not distinguish explicitly between amyloid-β-and tau-related alterations. Notably, tau pathology has recently been associated with epigenetic changes in model systems. In Drosophila, tau overexpression has been shown to relax heterochromatin 6, 7 . On the other hand, there is also evidence for a physiological function of nuclear tau in maintaining and regulating heterochromatin which may be lost by pathologically phosphorylated tau 8 . However, whether these mechanisms cause major chromatin alterations in the human AD brain, translate to transcriptional alterations, and are restricted to heterochromatic regions remains unknown.
Here, we studied the acetylation of the ninth lysine of histone 3 (H3K9Ac), which marks transcriptionally active open chromatin, genome-wide in the dorsolateral prefrontal cortex (DLPFC) of 669 subjects. Our data support the hypothesis that tau but not amyloid- causes major chromatin remodeling. We mapped the location of these alterations genome-wide, characterized the architecture of these large areas of coordinated chromatin remodeling, replicated them in transcriptomic data, demonstrated that tau is sufficient to cause such chromatin rearrangement prior to tangle formation, and identified a compound that may attenuate this chromatin perturbation.
Results

Tau but not amyloid- pathology has a broad effect on histone acetylation in the human brain
We studied the acetylation of histone 3 lysine 9 (H3K9Ac) in the DLPFC of 669 participants enrolled in either the Religious Order Study (ROS) or the Rush Memory and Aging Project (MAP), two longitudinal studies of aging and dementia 9, 10 . Participants were not demented upon study entry. At autopsy, neuropathologic examination was performed and quantitative measurements of the density of phosphorylated tau tangles and the burden of amyloid- were obtained (Fig. 1a) . A wide spectrum of tau tangles and amyloid- burdens with a moderate correlation of =0.48 between these two AD pathologies was observed in our subjects (Fig. 1b) . ChIP-seq was performed in isolated gray matter from frozen DLPFC samples to generate genome-wide H3K9Ac profiles. A median of 55 million 36 bp single-end reads were sequenced per sample (Supplementary Excel File 1). Demographic characteristics of the subjects are given in Table 1 .
We found 26,384 H3K9Ac peaks or "domains" which showed a distinct signal above the genomewide background in at least 100 of the 669 subjects. As with DNA methylation 4 , there is limited interindividual variability: the average correlation of domains between two individuals was 0.98, despite the vast differences in life experiences between these older individuals. Nearly half (41%) of the genomic regions covered by H3K9Ac domains in our data were annotated as containing an active transcription start site, and more than a quarter (27%) were annotated as being in an enhancer site (Fig. 1c ) based on the chromatin state annotation generated for this cortical region by the Roadmap Epigenomics Project (sample E073; a MAP subject with minimal neuropathology) 11 . We thus binned H3K9Ac peaks into "promoter" (n=15,225), "enhancer" (n=8,071) and "other" (n=3,088) domains (Supplementary Fig. 1a d) for subsequent analyses. Using RNA-seq data from the same region in a subset of subjects (n=500),
we verified the expected positive correlation between H3K9Ac and transcriptional activity (Fig. 1d ).
To distinguish between tau-and amyloid--related epigenomic changes, we modeled both pathologies simultaneously as explanatory variables in a regression model with the H3K9Ac levels as the outcome. At a false discovery rate of 0.05, 23% of H3K9Ac domains showed an association with tau whereas only 2% were associated with amyloid- (Fig. 1e , Supplementary Excel File 2). Only a few domains (n=88) had acetylation levels that were significantly associated with both pathologies.
This is a striking and unexpected difference in the impact of tau and amyloid- and it may be related to the fact that tau pathology initially accumulates intracellularly and may directly affect neuronal chromatin organization, whereas amyloid-is secreted and affects cells extracellularly. For tau, the largest proportion of associated domains was observed among promoter regions ( Fig. 1f ), but the estimated effect sizes were similar for domains found in promoters, enhancers and other regions (Supplementary Fig. 1e -f), indicating that the mechanism driving these associations is not specific for a type of domain. The greater average read depth at promoters probably explains the larger number of significant domains in these regions. Interestingly, known AD risk loci 1 were not enriched in tauassociated H3K9Ac domains: out of 39 H3K9Ac domains within 50 kb of 19 known AD loci, only 9
were associated with tau, corresponding to the genome-wide relative frequency of 23% (Supplementary Table 1 ).
Next, we investigated whether tau-related changes in H3K9Ac led to functional consequences by analyzing our RNA-seq data: we repeated the simultaneous evaluation of amyloid and tau pathology for 18,257 out of 24,594 active transcripts that could be mapped to an H3K9Ac domain. We observed a positive but weak correlation of 0.14 between the coefficients for tau (0.12 for amyloid) from the transcription and the H3K9Ac data: in general, epigenomic and transcriptomic data showed the same direction of effect ( Supplementary Fig. 1h-i Fig. 1g ).
Spatial pattern of alterations in H3K9Ac indicates tau-induced remodeling of higher-order chromatin structure
Because of the large number of tau-associated H3K9Ac domains, we evaluated the spatial distribution of tau-associated domains using a "Chicago Plot" that presents the physical location, significance, and directionality of each tested domain's association with tau ( Fig. 2a , Supplementary   Fig. 2a ). Throughout the genome, we find large-scale genomic segments whose H3K9Ac domains were coordinately enriched for associations with tau. Unlike genome-wide SNP studies where we see very small genomic regions being associated with disease because linkage disequilibrium is observed only over ~60 kilobase pairs (kbp) in most regions of the human genome 12 , we see a clustering of diseaserelated epigenomic associations in certain segments of the genome that cover several megabase pairs (Mbp). These results suggest that a physical aspect of the chromosome may be implicated in disease.
To define the boundaries of these large-scale segments we applied a segmentation algorithm 13 to our data, and this method divided the genome into 178 segments within which domains display a similar tau association (Fig. 2a) . The median size of these segments was 5.2 Mbp, and they contain a median of 79.5 H3K9Ac domains per segment. In contrast to tau, no similar spatial pattern was observed for domains associated with amyloid-pathology ( Supplementary Fig. 2b ), suggesting a fundamental difference in the relation of these pathologies to the human cortex' epigenome.
At the megabase pair scale, chromatin is spatially organized into type A and type B compartments. 14 Type A compartments are primarily characterized by open and type B compartments by closed chromatin. To study whether the spatial chromatin architecture underlies the observed spatial pattern of H3K9Ac alterations, we derived a compartment map from previously published Hi-C data of the cortical and subcortical plate of a human fetal brain. 15 The genome was divided into 636 compartments and H3K9Ac domains were mapped to compartments. Figure 2a shows the locations of H3K9Ac domains and A/B compartments for chromosome 1. Genome-wide, the majority of H3K9Ac domains (70%) were located in type A compartments, but we also observed 223 type B compartments out of 507 compartments that contained at least five H3K9Ac domains. For these 507 compartments, we calculated the mean tau effect on H3K9Ac and found a significantly larger tau effect in type A compartments ( Fig. 2b) indicating that the tau effect on H3K9Ac is associated with the spatial chromatin organization.
A critical element of chromatin structure is the nuclear lamina because it provides anchor points that couple chromatin to the lamina. Nuclear lamina is associated with repressive chromatin and type B compartments. Recent work in Drosophila suggests that tau can disrupt lamina function and thereby induce heterochromatin relaxation 6 . To elucidate the role of the lamina in our observations that center on euchromatin, we calculated the lamina association of our tau-defined segments as the proportion of lamina-associated domains (LADs) within a segment using previously published genome-wide DamID lamin B1 data from the human HT1080 fibrosacoma cell line 16 . Even though some LADs are cell type specific, the majority of LADs are strongly conserved, so that LADs derived from human fibroblasts are still useful for annotating whole brain tissue 16, 17 . We plotted the segments' lamina association versus the average tau effect of all H3K9Ac domains within a segment (Fig. 2c) . The negative correlation (ρ=-0.86) indicates that the effect of increasing tau pathology on single H3K9Ac domains varies depending on the chromatin states of the surrounding genomic region. In fact, the 178 genomic segments within which tau associations are correlated explain 29% of the variance of the tau effects observed across all 26,384 H3K9Ac domains. Thus, these observations reflect large-scale tau-induced changes in chromatin structure.
We next evaluated our RNA-seq data and found that each segments' mean tau effects obtained from the RNA-seq data was highly correlated (ρ=0.83) with the mean tau effects from the H3K9Ac data ( Fig. 2d) , reflecting a shift in average gene transcription that is related to the burden of tau pathology and is concordant with the segments' chromatin alterations. However, in line with the weak correlation of alterations in H3K9Ac and RNA levels at the single transcript level, only 2% of the variance of taurelated effects in RNA-seq data could be explained by the segments defined with the chromatin data.
This suggests that, while large-scale epigenomic changes explain some of the effect of tau on the transcriptome, other regulatory mechanisms must also be influenced by this neuropathologic process.
We then speculated that other epigenetic marks may show similar tau-related patterns: in evaluating our DNA methylation data from the same brain region 4 , we found consistent evidence for a perturbation of chromatin architecture. Specifically, we binned CpG's into four groups using the tissue specific reference chromatin state map from the Roadmap Epigenomics Project 11 (sample E073): active transcription start sites, enhancers, weakly transcribed regions and quiescent regions. These four chromatin states cover most of the CpGs in our data set, and we repeated the segment-based analysis for each group of CpG's. As shown in Fig. 2e , a negative correlation between tau effects on DNA methylation and nuclear lamina association was observed in enhancers, quiescent regions and weakly transcribed regions, which is in agreement with the paradigm that high methylation of gene bodies is a feature of active genes 18 . The variance of tau effects in DNA methylation data that could be explained by the H3K9Ac derived segments ranged between 6% for enhancer, 4% for transcribed regions, and 1% for quiescent regions. By contrast, no distinct correlation was observed at active transcription start sites (explained variance < 1%), in line with previous work reporting that promoter regions are spared from altered methylation levels in the presence of other diseases like leukemiaTo validate our findings in an independent set of samples, we assessed a published transcriptomic data set from the temporal cortex of subjects from a late onset AD (LOAD) case-control study 20 .
Because quantitative amyloid- and tau burdens were not available, we compared samples with AD diagnosis (n=202) to controls (n=90; non-AD and non-progressive supranuclear palsy (PSP) diagnosis) and calculated the mean AD-related change in transcription over the genes within each of the 178 genomic segments defined using our H3K9Ac data. Although we could not distinguish the tau from the amyloid- effects in these data, we did confirm the presence of a strong negative correlation (ρ=-0.71) between the segments' nuclear lamina association and AD-related transcriptional changes (Fig. 2e ).
Similar to our RNA-seq data, 4% of the variance of AD effects in the transcriptomic data of the LOAD study could be explained by the segments. Nevertheless, as in our RNA-seq data, the mean tau-related changes in the H3K9Ac data were positively correlated (ρ=0.65) with the mean AD-related changes in the transcription data from this LOAD study, validating our observation. The genomic locations of the 178 segments, their annotation and the average tau or AD effects from the different data sets are provided in Supplementary Excel File 4.
Since the data analyzed so far were generated from bulk tissue, it is critical to assess whether the observed alterations may be driven by changing cell type compositions. We estimated the proportion of NeuN + cells using the DNA methylation profiles 21 and, as expected, observed a significant association (p=0.02) between the proportion of NeuN + cells and pathologic AD diagnosis indicating that cell type composition might be a confounder. However, the coefficients for tau derived from a model adjusted for the proportion of NeuN + cells fitted on a subset of subjects that have both DNA methylation and H3K9Ac data were highly correlated (ρ=0.99) with the tau coefficients from the unadjusted model ( Supplementary Fig. 5h) 23 . Since tau and amyloid- loads were not reported in these subjects, we estimated the AD effect instead of the tau effect for each gene. The AD effects were then averaged within each of the 178 genomic segments defined in our H3K9Ac data, and the correlation with the segment's nuclear lamina association was calculated. Again, we observed a negative correlation of ρ=-0.64 (Fig. 2e) , and the correlation of these neuronal data with the average tau effect in our H3K9Ac data was ρ=0.67. Similar to the tissue transcriptomic data, 2% of the AD effect variance were explained by the segments. Interestingly, the original report of these neuronal data specifies that the investigators selected neurons for laser capture that were lacking neurofibrillary tangles; this indicates that the observed AD-related transcriptional changes are occurring early in pathogenesis, prior to the accumulation of tangles 23 . Since the transcriptional changes consistent with our epigenomic changes are found in purified neurons, they are likely to be cell-autonomous for neurons; however, we cannot rule out at this time that other cell types may also be affected.
H3K9Ac data from tau mouse models suggest similar structural changes in the murine brain epigenome that involve the nuclear lamina
To explore whether the epigenomic changes that we found in human brain are recapitulated in mouse models known to accumulate tau, we generated hippocampal H3K9Ac ChIP-seq profiles from two different mouse models at (1) an early time point and (2) a late stage of neurodegeneration (Supplementary Table 2 ). Specifically, we studied 6 and 11 months old mutant tau mice (MAPT P301S), which start to accumulate phosphorylated tau in neurons by 6 months 24 . Wild-type mice of the same age were used as controls. The second mouse model was the CK-p25 model, which is characterized by increased amyloid-β levels early after p25 induction followed by increased tau phosphorylation and neuronal loss at later stages 25, 26 . Three months old CK-p25 mice were studied 2 weeks and 6 weeks after p25 induction and were compared to CK littermate controls. In total, we found 44,165 H3K9Ac domains across the epigenome of both mouse models. Tau mice showed less significantly altered H3K9Ac domains compared to the CK-p25 mice, especially at the early stage of 6 months ( Fig. 3a) . Chicago plots did not show the explicit spatial pattern observed in human cortex, possibly because of the low sample size of 3 replicates per time point. We then classified the mouse H3K9Ac domains into two bins: "close to lamina" (if domain <50 kb from a LAD) or "distant to lamina" based on published DamID lamin B1 data from mouse embryonic fibroblasts 16 . As anticipated, we observed smaller differences between AD mice and control mice in H3K9Ac domains that were located in the proximity of LADs ( Fig. 3b-c ). This observation was consistent for both mouse models and more distinct at the later time points during which the pathology has accumulated more extensively, confirming our observations from the human cortex where the effect of tau was smaller in segments enriched with LADs.
Induced neurons overexpressing MAPT demonstrate chromatin structure alterations
Given the evidence from neuronal expression data that the observed changes of chromatin structure are likely to be occurring in neurons, we assessed whether overexpression of the 4R isoform of MAPT, which encodes the tau protein, in forebrain neurons derived from human induced pluripotent stem cells (iNs) could recapitulate the epigenomic changes that we found in our cortical H3K9Ac data. With fAD mutation, this model system induces AD-related features such as the intracellular accumulation of phosphorylated tau 27 . To characterize the epigenomic changes in this in vitro model system, we used the Assay for Transposase-Accessible Chromatin with sequencing (ATAC-seq) to map genome accessibility 28 . In contrast to anti-H3K9Ac ChIP-seq, ATAC-seq generates reads at all open regulatory elements where the Tn5 transposase can access exposed DNA. We therefore expect to observe ATACseq peaks in the vicinity of nucleosomes carrying the H3K9Ac mark that we targeted with the ChIP-seq assay, and additional peaks at enhancers and insulators that might not be marked by H3K9Ac.
All iNs were derived from the same iPSC line, and we observed 40,637 ATAC domains that have a distinct peak in at least 4 of our 18 samples. Each sample consisted of 2-3 pooled individual wells of transfected iNs; 9 samples represented independent transductions of MAPT-overexpressing iNs. The remaining 9 samples were control iNs transduced with a GFP overexpressing construct. Samples were generated in 3 experimental batches of independent differentiations. ATAC domains were annotated with chromatin states of hESC-derived neurons (sample E010) from the Roadmap Epigenomics overlapped one of the H3K9Ac domains from our whole brain tissues, but only 17% of the enhancer domains were included in our set of cortical H3K9Ac enhancer domains ( Fig. 4b ) indicating that H3K9Ac is not an explicit enhancer marker. Assessing these domains in the other direction, the majority of cortical H3K9Ac domains were overlapped by at least one ATAC domain (Fig. 4c) . Thus, while there are important differences between the two sets of profiles, there is good overlap, particularly in TSS where the bulk of the tau effect is observed in our H3K9Ac tissue-level data.
In total, 747 out of 40,637 ATAC domains showed a difference in their chromatin accessibility at an FDR of 0.05 when comparing the MAPT overexpressing iNs to control iNs infected with a nonrelevant vector (Fig. 4d ). The Chicago plots in Fig. 4e and Supplementary Fig. 2c depict large genomic segments of predominantly concordant tau-related changes; segments were defined using the same segmentation algorithm that we used for the cortical H3K9Ac data, and are indicated by purple segments. In iNs, we found 99 segments that explained 11% of the variance of tau effects observed for single ATAC domains (Supplementary Excel File 6). As seen in the H3K9Ac data, the tau effect differed significantly between type A and type B compartments (Fig. 4f) , and the average tau effect of the segments correlated (=0.92) with the proportion of LADs in the segment (Fig. 4g) suggesting the presence of changes in chromatin arrangement. These results were found consistently in each of the three batches ( Supplementary Fig. 4d-j) . Interestingly, in contrast to the H3K9Ac changes observed in human and in mouse brain tissue, segments containing many LADs showed a large positive average tau effect indicating that chromatin relaxation preferentially occurred in lamina-associated segments in this in vitro system. Concordantly, when looking at the human fetal brain A/B compartments, the tau effect observed in human brain H3K9Ac data was negatively correlated with the tau effect in iNs (Fig. 4h ).
To verify that the model system presents a tau effect that is the inverse of what we see in the human cortex, we repeated the iN experiment with anti-H3K9Ac ChIP-seq and estimated the effect size of tau for each of the 34,988 detected H3K9Ac domains. Then, using the 178 genomic segments derived from the cortical H3K9Ac data and calculated the segments' average tau effect in (i) iN H3K9Ac data and
(ii) iN ATAC data to compare it to the brain tissue H3K9Ac data (Fig. 4i, Supplementary Excel File 4) .
The H3K9Ac and ATAC data from iN's consistently indicate that tau is associated with chromatin opening in genomic segments with a high fraction of lamina association. Thus, segments of the genome are significantly affected by tau pathology in vivo and in vitro, but the direction of effect is reversed in relation to tau pathology, which accumulates over decades in the human brain and over 14 days in our MAPT overexpressing iN model system.
The Hsp90 inhibitor 17-DMAG is a candidate drug for attenuating tau-related alterations of chromatin structure
To find putative drugs with the potential to protect neurons from tau toxicity, we scanned the To assess the effect of 17-DMAG, we treated three independent cultures of MAPT overexpressing iNs with 17-DMAG at a concentration of 3 nM for 24 hr before harvesting (on day 31), based on published studies 32 . The differences between the treated MAPT overexpressing iNs and the respective controls were calculated for each of the 40,637 ATAC domains defined in iN. The variance of these tau-induced differences was then decomposed into between-segment and within-segment variance using the 99 tau-associated chromosomal segments derived for the iNs using ATAC-seq data. The prediction is that if 17-DMAG attenuates the tau effect on chromatin organization, the variance explained by the segments (i.e. the between-segment variance) should decrease for the 17-DMAG treated iNs. In our experiment, we observed such a protective effect of 17-DMAG ( 
Discussion
Our epigenome-wide association study revealed that tau pathology is associated with broad changes in the brain's epigenome. We observed large genomic segments of several megabases within which H3K9Ac domains showed similar tau-associated gains or losses of histone acetylation. At the megabase pair scale, the genome is organized into two major types of compartments, A and B, defined by patterns observed in Hi-C interaction maps 14 . Type A compartments are characterized by euchromatin which is transcriptionally active whereas the inactive type B compartments exhibit high chromatin density. These two major types of compartments are essential for chromatin organization 33 and cell identity 34 , and impose a cis-and trans-correlation structure on epigenetic marks 35 . We demonstrated that the effect of tau on H3K9Ac differed between type A and type B compartments and that the segments observed in the Chicago plot (Fig. 2a) reflected the higher-order chromatin structure.
Thus, tau appears to be preferentially affecting certain elements of nuclear architecture and chromosomal organization.
The nuclear lamina is a key element in the spatial organization of chromatin and is associated with inactive B compartments. Previous work in Drosophila suggested that the lamin nucleoskeleton is disrupted in tauopathies, which causes heterochromatin relaxation and mediates neuronal cell death 6, 7 .
In line with this hypothesis, we observed a strong correlation between the effect of tau in a genomic segment and the nuclear lamina association of that segment. However, we measured the euchromatic mark H3K9Ac and it remains unclear how this mark relates to heterochromatin relaxation.
The association of tau pathology with alterations in chromatin architecture is not specific to the H3K9Ac chromatin mark and has functional consequences: we replicated the presence of the segments with coordinated alterations in relation to tau pathology in both DNA methylation and transcriptomic data from the same persons. Further, we find the same pattern of results in publically available transcriptomic data from a different cohort, and a second dataset from laser-captured neurons further refines the observation by implicating a specific cell population. Even though the pattern was less distinct in the various transcriptomic data sets, demonstrating the presence of these transcriptional perturbations in relation to tau is important in understanding the consequences of these alterations. Not all epigenetic changes directly translate to altered transcription. In addition, if chromatin alterations induce the transcription of epigenetically silenced genes, transcription may occur at a low level in a tissue sample, and we may thus be under-estimating the extent of transcriptional alterations in tissuelevel RNA-seq data.
We employed AD mouse models and MAPT overexpressing iNs to further explore our findings and to address some of the limitations of our human cortex study. Looking at the results from our iN experiments, we demonstrated that MAPT overexpression is sufficient to induce chromatin reorganization in neurons. Further, this event occurs prior to tangle formation and neuronal cell death in our model system: perturbation of epigenomic architecture may therefore be an early event in tau pathology. This is an important point that we cannot address with our cross-sectional human H3K9Ac brain data. In the CK-p25 mouse model, we detected altered H3K9Ac levels depending on the proximity of the H3K9Ac domain to the nuclear lamina two weeks after p25 induction. For the same mouse model at the same time point, a study reported altered localization of lamin in hippocampal neurons indicating a dispersion of the nuclear lamina membrane that could affect the chromatin organization 39 . This effect was stronger after 4 weeks in line with our observations after 6 weeks and preceded apoptosis 39 . Finally, our observation in the neuronal expression data further supports the hypothesis that tau-induced epigenomic changes are an early event that occurs downstream of pathologic tau accumulation, but before neurofibrillary tangles develop since the data was generated from neurons free of tangles 23 .
Interestingly, we observed large positive tau effects on H3K9Ac in lamina free regions of the human cortex and mouse brain, but the direction of the association was reversed for iNs. This is an intriguing result and suggests a complex but definitive interaction between tau and chromatin structure.
iNs grow in vitro in the absence of the three dimensional context of the cerebral cortex and do not interact with non-neuronal cells. The inverse directionality that we see at an early time point after MAPT overexpression could be an initial response of iNs to a rapid accumulation of tau (compared to accumulation over decades in the human brain), in line with recent work suggesting that nuclear tau also has a physiological function in assembling and maintaining heterochromatin 8 . Importantly, the segmental pattern and the association of the tau effect with the proportion of LADs in the segments is seen in both the human cortex and iNs, suggesting the involvement of the same mechanism. Thus, while more work is required to delineate the molecular events happening in vivo and in vitro, iNs overexpressing tau may be a useful model system with which to investigate and target tau-induced epigenomic changes in neurons. This is illustrated by our testing of an Hsp90 inhibitor that is predicted to block the effects of tau based on our brain data: 17-DMAG attenuates the chromatin alterations induced by tau in iN's.
Overall, we have characterized changes throughout the epigenome of the human AD brain and showed that tau induced alterations of the spatial chromatin organization. The effect of these alterations propagate into the transcriptome. Our data supports the hypothesis that the nuclear lamina and the transcription factor CTCF are key elements in mediating tau toxicity in vivo and in vitro, and we demonstrated that iNs are a useful model system to further study tau-associated chromatin changes and to screen for drugs such as 17-DMAG that might prevent or reverse these chromatin alterations. 
Author Contributions
Methods
ROS/MAP cohort and pathologic characterization
All participants were enrolled in the Religious Orders Study (ROS) 9 
H3K9Ac ChIP-seq data pre-processing and peak detection
Single-end reads were aligned by the BWA algorithm against the human reference genome 
Statistical analysis of H3K9Ac ChIP-seq data
For each sample and H3K9Ac domain, we counted the number of ChIP-seq reads that fell into the domain 45 . Read counts Y were assumed to follow a negative binomial distribution Y ~ NB(μ,θ) with mean μ and dispersion parameter θ. A log-linear regression model (1) was fitted for each H3K9Ac domain separately using the R package MASS. The offset log(n) accounts for different total numbers of reads n (summed over all domains) per sample. Coefficients βt and βa model the effect of the observed square root-transformed tau and amyloid-β levels on the H3K9
log(E(Y)) = log(n) + β0 + xtβt + xaβa + zγ
acetylation levels. Coefficients were tested by Wald tests and the false discovery rate (FDR) was calculated to account for multiple testing. Vector γ models the biological covariates age and gender as well as the technical covariates post mortem interval, batch and cross-correlation, which is a measure of the efficiency of the ChIP.
Statistical analysis of transcription and methylation data
ROS/MAP RNA-seq data from the DLPFC were generated as previously described 46 DNA methylation data were generated as described elsewhere 4 and can be downloaded from Synapse (Synapse: syn3157275). Illumina 450K bead arrays were processed by the Illumina
GenomeStudio to obtain relative methylation levels ("beta values"). Relative methylation levels were assumed to follow a beta distribution and modeled by CpG-wise beta regression models using the probit function as link function 48 . Tau, amyloid-β, age, gender, post mortem interval, batch and bisulfite conversion rate were used as covariates.
Gene expression data from the Mayo LOAD study 20 was downloaded at Synapse (Synapse: syn3157225) 49 . The neuronal expression data set was downloaded from Gene Expression Omnibus (GEO: GSE5281) 23 . Analyses of these data sets are described in the Supplementary Notes.
Determining genomic segments of concordant tau-related changes
Tau p-values from model (1) were log-transformed and the signs of the respective tau coefficients βt were assigned to the transformed p-values to account for the direction of the association. The circular binary segmentation algorithm 13 implemented in the R package DNAcopy was then applied to the transformed p-values with the corresponding genomic positions of the H3K9Ac domains. We used the default value of α=0.01 to accept new change-points. After the segments were determined, we calculated the weighted mean of all tau effect sizes βt within the segment using the coefficients' inverse standard deviation as weights. Mean effect sizes were obtained in the same manner for the other data sets shown in Fig. 2e and 4g by calculating the weighted average of the respective coefficients for either tau, Alzheimer's disease diagnosis or MAPT overexpression. Supplementary Excel File 4 contains all 178 segments and the mean effect sizes from all data sets. Small segments (< 20 H3K9Ac domains or < 20 active transcripts) and segments on sex chromosomes were excluded when calculating correlation coefficients reducing the number of segments to 138. Genomic segments defined on the ATAC-seq data from induced neurons were identified in the same manner. All 99 ATAC-seq derived segments are given in Supplementary Excel File 6. Exclusion of small segments (< 20 ATAC domains) and segments on sex chromosomes reduced the number of segments to 89.
A/B compartment and lamina-associated domain annotation
Human fetal brain A/B compartments were obtained from a published Hi-C data set (GEO:
GSE77565) as described in the original publication. 15 Briefly, Pearson correlation matrices were calculated from the intra-chromosomal observed/expected 40 kbp binned interaction matrices. For each chromosome, the sign of the first principal component obtained from the correlation matrix was used to categorize bins as type A or B compartment.
Genomic segments were annotated with their lamina association using published DamID data for Lamin B1 in human fibroblasts (GEO: GSE22428). 16 Probes of the DamID array were classified into nuclear lamina bound or unbound in the original work. We re-mapped the probes against genome GRCh37 and defined the lamina association of a segment as the ratio of nuclear lamina bound probes to all probes in the segment. To sort segments in Figures 2e and 4i , chromatin accessibility was calculated from chromatin state annotation of sample E073 (DLPFC) from the Roadmap Epigenomics Project. Chromatin accessibility was defined as the fraction of the segment that was annotated with any chromatin state other than heterochromatin, repressed polycomb, weak repressed polycomb or quiescent/low. These four chromatin states exhibited the lowest DNA accessibility measured by DNase-seq 11 . As expected, chromatin accessibility was negatively correlated with lamina association in the DLPFC (ρ=-0.89): that is, segments of more open chromatin were less likely to include a LAD.
Mouse models
All mouse work was approved by the Committee on Animal Care of the Division of Comparative
Medicine at MIT and complied with the relevant ethical regulations. Adult (3 months old) female double-transgenic CK-p25 mice 25 and their respective control littermates were used for the experiments. Brain tissue was collected at either 2 or 6 weeks after p25 induction. For the Tau (P301S) mouse model 24 , adult female 6 months old and male 11 months old transgenic mice with age-and gender-matched wild-type mice as controls were used. Upon dissection the tissue was flash-frozen in liquid nitrogen. No animals were excluded from the study. Hippocampal tissue was extracted and ChIP-seq was applied as described for the human brain tissue using the Abcam antibody ab#4441 (lot numbers GR196840-1 and GR207546-1). Supplementary Table 2 summarizes the number of replicates generated for the different time points.
Pre-processing and statistical analysis of the mouse H3K9Ac ChIP-seq data
The murine H3K9Ac ChIP-seq data was pre-processed similar to the human DLPFC ChIP-seq data.
BWA was used to map reads against the reference assembly NCBI m37. Quality measures were calculated (Supplementary Excel File 8) as described for the human data with the exception that we did not require samples to have ≥ 15x10 6 unique reads, because CKp25 samples were sequenced at a lower coverage. H3K9Ac domains were defined as regions that were covered by a peak in at least 4 (17%) out of the 23 samples (n=12 CKp25; n=11 tau) resulting in 44,165 domains. For each mouse model and time point, we compared 3 (or 2) AD model mice to 3 respective control mice using voom implemented in the R package limma 50 . Voom has been designed for small sample sizes and provides reliable domain-specific estimates of the variance by estimating the mean-variance trend using information from all domains. The voom method is incorporated in a linear regression framework with log2-transformed reads per million (log2 rpm) as outcome. A model was fitted for each domain and the cross correlation was added as technical covariate in addition the AD/control status variable.
Induction of human neuronal cells overexpressing MAPT
The iPSC line used in this study (YZ1) was originally generated from the IMR-90 cell line (ATCC) and characterization of this line was described previously. 51 Due to a karyotype abnormality in a small subset of cells, monoclonal isolates were obtained and confirmed to be karyotypically normal and pathogen free prior to initiating this study. The iPSC line used was confirmed to be of the correct identity prior to and at the conclusion of the study using short tandem repeat (STR) profiling (Genetica Cell Line Testing). Neurons were generated from the direct conversion of induced pluripotent stem cDNA compared to controls. In total, 9 MAPT OE and 9 control iNs were generated in 3 batches (differentiation rounds) of triplicate wells.
17-DMAG treatment of induced neurons
The Ampure XP SPRI beads and eluted in 12 ul of water. We quantified with Qubit HS DNA assay and assessed for quality using a Bioanalyzer High-Sensitivity DNA analysis Kit. 20 ng of each sample were pooled and diluted to 4nM using an estimated library length of 300 bp for all and submitted to the Broad Institute's Genomics Platform for Illumina HiSeq2500 for 25 bp paired end reads.
ATAC-seq data pre-processing and peak detection
Paired-end reads from ATAC-seq were aligned by the BWA algorithm against the human reference genome GRCh37 42 . MACS2 was applied without control library to each sample using fragment sizes obtained from the paired alignments and a q-value cutoff of 0.001 43 . Our ChIP-seq quality control pipeline was adapted for ATAC-seq: Instead of cross-correlation we calculated the median insert size and verified that the distribution of insert sizes showed a periodicity equal to the helical pitch of DNA (Supplementary Excel File 5). ATAC domains were defined as genomic regions covered by a peak in at least 4 (22%) of our 18 samples (n=9 MAPT OE; n=9 controls). Domains less than 50 bp away from each other were merged. In total, we obtained 40,637 ATAC domains. ATAC domains were annotated with chromatin states obtained from hESC-derived neurons included in the Roadmap Epigenomics Project (sample E010, core 15-state model) 11 . ATAC domains were clustered based on the proportion of chromatin states within the domains and classified into TSS, TSS flanking, enhancer or other domain as described in the Supplementary Notes ( Supplementary Fig. 4a-c) .
Statistical analysis of ATAC-seq data
The number of read-pairs in each ATAC domain and sample were obtained and rpm values were 
H3K9Ac Chip-seq data from induced neurons
H3K9Ac ChIP-seq data from iNs were generated and processed as described for the DLPFC tissue samples (Supplementary Excel File 5 ). Pooled input DNA from all three samples (n=2 MAPT OE, n=1 control) were used as control library during peak detection. Peaks that were detected in at least two of the three samples were defined as neuronal H3K9Ac domains (n=34,988) and used for subsequent analyses. The voom method was applied to test for differences between MAPT OE and control neurons 50 . In addition to the tau status variable (n=2 MAPT OE, n=1 control), cross-correlation was added as covariate to adjust for technical variability. 
Search for potential drugs in the Connectivity
Data availability
Human cortical ChIP-seq data was deposited at Synapse (Synape: syn4896408). Murine ChIP-seq data (GEO: GSE97560) and ATAC-seq data from iNeurons (GEO: GSE97409) are available at Gene Expression Omnibus. 
